Skip to main content

Table 2 Summary of STAT3 inhibitors in clinical trials

From: STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review

Inhibitors

Target

ClinicalTrials ID

Condition or disease

Phase

References

STAT3 DECOY

STAT3

NCT00696176

Head and neck cancer

Early phase 1

[130]

AZD9150

(IONIS-STAT3Rx or ISIS-STAT3Rx)

STAT3

NCT01563302

Advanced cancers, DLBCL

Phases 1 & 2

[131, 132]

NCT02417753

Ovarian cancer, GIC

Phase 2

NCT01839604

HCC

Phase 1

NCT02983578

GIC, lung cancer, etc.

Phase 2

NCT03527147

NHL, DLBCL, NHL, DLBCL

Phase 1

NCT02549651

DLBCL

Phase 1

NCT03421353

Advanced solid tumors

Phases 1 & 2

TTI-101

(C188–9)

STAT3

NCT03195699

Breast cancer, HNSCC, NSCLC, etc.

Phase 1

[133]

OPB-51602

STAT3

NCT02058017

Nasopharyngeal carcinoma

Phase 1

[134]

NCT01867073

Advanced solid tumors

Phase 1

NCT01423903

Advanced cancer

Phase 1

OPB-31121

STAT3

NCT00955812

Advanced cancer, solid tumor

Phase 1

[136]

OPB-111077

STAT3

NCT01711034

Solid tumors

Phase 1

[137]

Napabucasin (BBI608 or GB201)

STAT3

NCT03647839

MCC

Phase 2

[135]

NCT03522649

Previously treated MCC

Phase 3

NCT02826161

NSCLC

Phase 3

NCT02993731

Pancreatic ductal carcinoma

Phase 3

Pyrimethamine

STAT3

NCT01066663

CLL, SLL

Phases 1 & 2

[138]

NCT03057990

Myelodysplastic syndromes

Phase 1

Simvastatin

STAT3

NCT02390843

Retinoblastoma, clear cell sarcoma, renal cell carcinoma, rhabdoid tumor, etc.

Phase 1

[139]

DSP-0337

STAT3

NCT03416816

Neoplasms

Phase 1

[140]

Cetuximab

EGFR

NCT01445405

Squamous carcinoma, head and neck cancer, etc.

Phase 1

[141]

Lapatinib

EGFR

NCT00105950

Breast neoplasms

Phase 2

[142]

Dasatinib

c-Src

NCT02680951

AML

Phase 1

[143]

SC-43

SHP-1

NCT03443622

Refractory solid tumor

Phase 1

[144]

ASN002

JAK

NCT02440685

Lymphoma, leukemia

Phases 1 & 2

[145]

SAR302503

JAK2

NCT01420783

Hematopoietic neoplasm

Phase 2

[146]

AZD1480

JAK2

NCT01112397

Solid malignancies

Phase 1

[147]

WP1066

JAK2

NCT01904123

Metastatic melanoma, recurrent glioblastoma, etc.

Phase 1

[148]

  1. AML Acute myeloid leukemia, CLL Chronic lymphocytic leukemia, DLBCL Diffuse large B-cell lymphoma, GIC Gastrointestinal cancer, HCC Hepatocellular carcinoma, HNSCC Head and neck squamous cell carcinoma, MCC Metastatic colorectal cancer, NHL Non-Hodgkin lymphoma, NSCLC Non-small cell lung cancer, SLL Small lymphocytic leukemia
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us